These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23460379)

  • 61. Shock and Early Death in Hematologic Patients with Febrile Neutropenia.
    Guarana M; Nucci M; Nouér SA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31405857
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis.
    Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Jacquy C; Burniat A; Steels E; Vallot F; Sculier JP
    Support Care Cancer; 2002 Apr; 10(3):181-8. PubMed ID: 11904782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.
    Lehrnbecher T; Phillips R; Alexander S; Alvaro F; Carlesse F; Fisher B; Hakim H; Santolaya M; Castagnola E; Davis BL; Dupuis LL; Gibson F; Groll AH; Gaur A; Gupta A; Kebudi R; Petrilli S; Steinbach WJ; Villarroel M; Zaoutis T; Sung L;
    J Clin Oncol; 2012 Dec; 30(35):4427-38. PubMed ID: 22987086
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
    Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
    Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.
    Chernobelski P; Lavrenkov K; Rimar D; Riesenberg K; Schlaeffer F; Ariad S; Mermershtain W
    Chemotherapy; 2006; 52(4):185-9. PubMed ID: 16675902
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
    Rapoport BL; Aapro M; Paesmans M; van Eeden R; Smit T; Krendyukov A; Klastersky J
    BMC Cancer; 2018 Sep; 18(1):917. PubMed ID: 30249215
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer.
    Hosmer W; Malin J; Wong M
    Support Care Cancer; 2011 Mar; 19(3):333-41. PubMed ID: 20179995
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes.
    Zuckermann J; Moreira LB; Stoll P; Moreira LM; Kuchenbecker RS; Polanczyk CA
    Ann Hematol; 2008 Feb; 87(2):139-45. PubMed ID: 17938926
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
    Freyer G; Kalinka-Warzocha E; Syrigos K; Marinca M; Tonini G; Ng SL; Wong ZW; Salar A; Steger G; Abdelsalam M; DeCosta L; Szabo Z
    Med Oncol; 2015 Oct; 32(10):236. PubMed ID: 26315712
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The impact of emergency department triage on the treatment outcomes of cancer patients with febrile neutropenia: A retrospective review.
    Alsharawneh A; Maddigan J; Gaudine A; Etchegary H; Gao Z
    Int Emerg Nurs; 2020 Jul; 51():100888. PubMed ID: 32622224
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.
    Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA
    J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
    Murakawa Y
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
    Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
    J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Which one is more effective, filgrastim or lenograstim, during febrile neutropenia attack in hospitalized patients with solid tumors?
    Sonmez OU; Guclu E; Uyeturk U; Esbah O; Turker I; Bal O; Budakoglu B; Arslan UY; Karabay O; Oksuzoglu B
    Asian Pac J Cancer Prev; 2015; 16(3):1185-9. PubMed ID: 25735353
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons.
    Feld R
    Clin Infect Dis; 1999 Sep; 29(3):503-7. PubMed ID: 10530436
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of febrile neutropenia in an acute oncology service.
    Sammut SJ; Mazhar D
    QJM; 2012 Apr; 105(4):327-36. PubMed ID: 22080099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.